{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,3,12]],"date-time":"2023-03-12T05:06:37Z","timestamp":1678597597318},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2008,7,15]],"date-time":"2008-07-15T00:00:00Z","timestamp":1216080000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2008,7,15]],"date-time":"2008-07-15T00:00:00Z","timestamp":1216080000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2008,12]]},"DOI":"10.1007\/s10637-008-9153-0","type":"journal-article","created":{"date-parts":[[2008,7,14]],"date-time":"2008-07-14T07:26:08Z","timestamp":1216020368000},"page":"553-559","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Phase \u0399 trial of weekly Docetaxel and daily Temozolomide in patients with metastatic disease"],"prefix":"10.1007","volume":"26","author":[{"given":"I.","family":"Tamaskar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Mekhail","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Dreicer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Olencki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Roman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Elson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R. M.","family":"Bukowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2008,7,15]]},"reference":[{"key":"9153_CR1","first-page":"4845","volume":"51","author":"MC Bissery","year":"1991","unstructured":"Bissery MC, Guenard D, Gueritte-Voegelein F, Lavelle F (1991) Experimental antitumor activity of taxotere (RP 56976, NSC 628503), a taxol analogue. Cancer Res 51:4845\u20134852","journal-title":"Cancer Res"},{"key":"9153_CR2","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1056\/NEJM199504133321507","volume":"332","author":"EK Rowinsky","year":"1995","unstructured":"Rowinsky EK, Donehower RC (1995) Paclitaxel (taxol). N Engl J Med 332:1004\u20131014 doi:10.1056\/NEJM199504133321507","journal-title":"N Engl J Med"},{"key":"9153_CR3","first-page":"385","volume":"35","author":"J-F Riou","year":"1994","unstructured":"Riou J-F, Petitgenet O, Combeau C, Lavelle F (1994) Cellular uptake and efflux of docetaxel (Taxotere\u00ae) and paclitaxel (Taxol\u00ae) in P388 cell line. Proc Am Assoc Cancer Res 35:385","journal-title":"Proc Am Assoc Cancer Res"},{"key":"9153_CR4","unstructured":"Taxotere package insert"},{"key":"9153_CR5","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/bjc.1992.57","volume":"65","author":"ES Newlands","year":"1992","unstructured":"Newlands ES, Blackledge GR, Slack JA, Rustin GJ, Smith DB, Stuart NS et al (1992) Phase I trial of temozolomide (CCRG 81045: M and B 39831: NSC 362856). Br J Cancer 65:287\u2013291","journal-title":"Br J Cancer"},{"key":"9153_CR6","first-page":"5846","volume":"47","author":"MF Stevens","year":"1987","unstructured":"Stevens MF, Hickman JA, Langdon SP, Chubb D, Vickers L, Stone R et al (1987) Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (CCRG 81045; M and B 39831), a novel drug with potential as an alternative to dacarbazine. Cancer Res 47:5846\u20135852","journal-title":"Cancer Res"},{"key":"9153_CR7","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/S0305-7372(97)90019-0","volume":"23","author":"ES Newlands","year":"1997","unstructured":"Newlands ES, Stevens MF, Wedge SR, Wheelhouse RT, Brock C (1997) Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials. Cancer Treat Rev 23:35\u201361 doi:10.1016\/S0305-7372(97)90019-0","journal-title":"Cancer Treat Rev"},{"key":"9153_CR8","first-page":"309","volume":"5","author":"SD Baker","year":"1999","unstructured":"Baker SD, Wirth M, Statkevich P, Reidenberg P, Alton K, Sartorius SE et al (1999) Absorption, metabolism, and excretion of 14C-temozolomide following oral administration to patients with advanced cancer. Clin Cancer Res 5:309\u2013317","journal-title":"Clin Cancer Res"},{"key":"9153_CR9","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1023\/A:1022592913323","volume":"61","author":"M Patel","year":"2003","unstructured":"Patel M, McCully C, Godwin K, Balis FM (2003) Plasma and cerebrospinal fluid pharmacokinetics of intravenous temozolomide in non-human primates. J Neurooncol 61:203\u2013207 doi:10.1023\/A:1022592913323","journal-title":"J Neurooncol"},{"key":"9153_CR10","doi-asserted-by":"crossref","first-page":"2762","DOI":"10.1200\/JCO.1999.17.9.2762","volume":"17","author":"WK Yung","year":"1999","unstructured":"Yung WK, Prados MD, Yaya-Tur R, Rosenfeld SS, Brada M, Friedman HS et al (1999) Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal brain tumor group. J Clin Oncol 17:2762\u20132771","journal-title":"J Clin Oncol"},{"key":"9153_CR11","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1054\/bjoc.2000.1316","volume":"83","author":"WK Yung","year":"2000","unstructured":"Yung WK, Albright RE, Olson J, Fredericks R, Fink K, Prados MD et al (2000) A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer 83:588\u2013593 doi:10.1054\/bjoc.2000.1316","journal-title":"Br J Cancer"},{"key":"9153_CR12","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1200\/JCO.1995.13.4.910","volume":"13","author":"NM Bleehen","year":"1995","unstructured":"Bleehen NM, Newlands ES, Lee SM, Thatcher N, Selby P, Calvert AH et al (1995) Cancer research campaign phase II trial of temozolomide in metastatic melanoma. J Clin Oncol 13:910\u2013913","journal-title":"J Clin Oncol"},{"key":"9153_CR13","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1200\/JCO.2000.18.1.158","volume":"18","author":"MR Middleton","year":"2000","unstructured":"Middleton MR, Grob JJ, Aaronson N, Fierlbeck G, Tilgen W, Seiter S et al (2000) Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 18:158\u2013166","journal-title":"J Clin Oncol"},{"key":"9153_CR14","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1097\/00001813-199701000-00013","volume":"8","author":"SR Wedge","year":"1997","unstructured":"Wedge SR, Porteous JK, Glaser MG, Marcus K, Newlands ES (1997) In vitro evaluation of temozolomide combined with X-irradiation. Anticancer Drugs 8:92\u201397 doi:10.1097\/00001813-199701000-00013","journal-title":"Anticancer Drugs"},{"key":"9153_CR15","doi-asserted-by":"publisher","first-page":"254","DOI":"10.3816\/CLC.2002.n.009","volume":"3","author":"CS Adonizio","year":"2002","unstructured":"Adonizio CS, Babb JS, Maiale C, Huang C, Donahue J, Millenson MM et al (2002) Temozolomide in non-small-cell lung cancer: preliminary results of a phase II trial in previously treated patients. Clin Lung Cancer 3:254\u2013258","journal-title":"Clin Lung Cancer"},{"key":"9153_CR16","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s11060-004-9176-0","volume":"71","author":"C Christodoulou","year":"2005","unstructured":"Christodoulou C, Bafaloukos D, Linardou H, Aravantinos G, Bamias A, Carina M et al (2005) Temozolomide (TMZ) combined with cisplatin (CDDP) in patients with brain metastases from solid tumors: a hellenic cooperative oncology group (HeCOG) phase II study. J Neurooncol 71:61\u201365 doi:10.1007\/s11060-004-9176-0","journal-title":"J Neurooncol"},{"key":"9153_CR17","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1200\/JCO.20.2.420","volume":"20","author":"D Bafaloukos","year":"2002","unstructured":"Bafaloukos D, Gogas H, Georgoulias V, Briassoulis E, Fountzilas G, Samantas E et al (2002) Temozolomide in combination with docetaxel in patients with advanced melanoma: a phase II study of the hellenic cooperative oncology group. J Clin Oncol 20:420\u2013425 doi:10.1200\/JCO.20.2.420","journal-title":"J Clin Oncol"},{"key":"9153_CR18","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1038\/sj.bjc.6690802","volume":"81","author":"M Brada","year":"1999","unstructured":"Brada M, Judson I, Beale P, Moore S, Reidenberg P, Statkevich P et al (1999) Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies. Br J Cancer 81:1022\u20131030 doi:10.1038\/sj.bjc.6690802","journal-title":"Br J Cancer"},{"key":"9153_CR19","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1016\/S0959-8049(00)00005-8","volume":"36","author":"T Giannakakis","year":"2000","unstructured":"Giannakakis T, Ziras N, Kakolyris S, Mavroudis D, Androulakis N, Agelaki S et al (2000) Docetaxel in combination with carboplatin for the treatment of advanced non-small cell lung carcinoma: a multicentre phase I study. Eur J Cancer 36:742\u2013747 doi:10.1016\/S0959-8049(00)00005-8","journal-title":"Eur J Cancer"},{"key":"9153_CR20","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1006\/gyno.2002.6786","volume":"87","author":"DT Rein","year":"2002","unstructured":"Rein DT, Kurbacher CM, Breidenbach M, Schondorf T, Schmidt T, Konig E et al (2002) Weekly carboplatin and docetaxel for locally advanced primary and recurrent cervical cancer: a phase I study. Gynecol Oncol 87:98\u2013103 doi:10.1006\/gyno.2002.6786","journal-title":"Gynecol Oncol"},{"key":"9153_CR21","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1007\/BF00873957","volume":"12","author":"BT Hill","year":"1994","unstructured":"Hill BT, Whelan RDH, Shellard SA (1994) Differential cytotoxic effects of docetaxel in a range of mammalian tumor cell lines and certain drug resistant sublines in vitro. Invest New Drugs 12:169\u2013182 doi:10.1007\/BF00873957","journal-title":"Invest New Drugs"},{"key":"9153_CR22","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1200\/JCO.2000.18.10.2095","volume":"18","author":"FA Shepherd","year":"2000","unstructured":"Shepherd FA, Dancey J, Ramlau R, Mattson K, Gralla R, O'Rourke M et al (2000) Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 18:2095\u20132103","journal-title":"J Clin Oncol"},{"key":"9153_CR23","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1200\/JCO.2006.09.8251","volume":"25","author":"M Di Maio","year":"2007","unstructured":"Di Maio M, Perrone F, Chiodini P, Gallo C, Camps C, Schuette W et al (2007) Individual patient data meta-analysis of docetaxel administered once every 3\u00a0weeks compared with once every week second-line treatment of advanced non-small-cell lung cancer. J Clin Oncol 25:1377\u20131382 doi:10.1200\/JCO.2006.09.8251","journal-title":"J Clin Oncol"},{"key":"9153_CR24","doi-asserted-by":"publisher","first-page":"8389","DOI":"10.1200\/JCO.2005.02.3739","volume":"23","author":"W Schuette","year":"2005","unstructured":"Schuette W, Nagel S, Blankenburg T, Lautenschlaeger C, Hans K, Schmidt EW et al (2005) Phase III study of second-line chemotherapy for advanced non-small-cell lung cancer with weekly compared with 3-weekly docetaxel. J Clin Oncol 23:8389\u20138395 doi:10.1200\/JCO.2005.02.3739","journal-title":"J Clin Oncol"},{"key":"9153_CR25","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1093\/annonc\/mdi018","volume":"16","author":"R Gervais","year":"2005","unstructured":"Gervais R, Ducolone A, Breton JL, Braun D, Lebeau B, Vaylet F et al (2005) Phase II randomised trial comparing docetaxel given every 3\u00a0weeks with weekly schedule as second-line therapy in patients with advanced non-small-cell lung cancer (NSCLC). Ann Oncol 16:90\u201396 doi:10.1093\/annonc\/mdi018","journal-title":"Ann Oncol"},{"key":"9153_CR26","doi-asserted-by":"publisher","first-page":"1996","DOI":"10.1038\/sj.bjc.6602241","volume":"91","author":"C Gridelli","year":"2004","unstructured":"Gridelli C, Gallo C, Di Maio M, Barletta E, Illiano A, Maione P et al (2004) A randomised clinical trial of two docetaxel regimens (weekly vs 3\u00a0week) in the second-line treatment of non-small-cell lung cancer. the DISTAL 01 study. Br J Cancer 91:1996\u20132004 doi:10.1038\/sj.bjc.6602241","journal-title":"Br J Cancer"},{"key":"9153_CR27","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1002\/cncr.23321","volume":"112","author":"E Rivera","year":"2008","unstructured":"Rivera E, Mejia JA, Arun BK, Adinin RB, Walters RS, Brewster A et al (2008) Phase 3 study comparing the use of docetaxel on an every-3-week versus weekly schedule in the treatment of metastatic breast cancer. Cancer 112:1455\u20131461","journal-title":"Cancer"},{"key":"9153_CR28","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1200\/JCO.2000.18.6.1212","volume":"18","author":"HJ Burstein","year":"2000","unstructured":"Burstein HJ, Manola J, Younger J, Parker LM, Bunnell CA, Scheib R et al (2000) Docetaxel administered on a weekly basis for metastatic breast cancer. J Clin Oncol 18:1212\u20131219","journal-title":"J Clin Oncol"},{"key":"9153_CR29","first-page":"32","volume":"25","author":"TM Loffler","year":"1998","unstructured":"Loffler TM (1998) Is there a place for \u201cdose-dense\u201d weekly schedules of the taxoids? Semin Oncol 25:32\u201334","journal-title":"Semin Oncol"},{"key":"9153_CR30","first-page":"1093","volume":"3","author":"M Dhodapkar","year":"1997","unstructured":"Dhodapkar M, Rubin J, Reid JM, Burch PA, Pitot HC, Buckner JC et al (1997) Phase I trial of temozolomide (NSC 362856) in patients with advanced cancer. Clin Cancer Res 3:1093\u20131100","journal-title":"Clin Cancer Res"},{"key":"9153_CR31","first-page":"4363","volume":"58","author":"CS Brock","year":"1998","unstructured":"Brock CS, Newlands ES, Wedge SR, Bower M, Evans H, Colquhoun I et al (1998) Phase I trial of temozolomide using an extended continuous oral schedule. Cancer Res 58:4363\u20134367","journal-title":"Cancer Res"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-008-9153-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-008-9153-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-008-9153-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-008-9153-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T18:33:21Z","timestamp":1678559601000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-008-9153-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,7,15]]},"references-count":31,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2008,12]]}},"alternative-id":["9153"],"URL":"https:\/\/doi.org\/10.1007\/s10637-008-9153-0","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,7,15]]},"assertion":[{"value":"22 April 2008","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2008","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2008","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}